Ovarian Serous Adenocarcinoma

Our findings emphasize that when imaging or cytology suggests multiorigin components, clinicians should pursue thorough intraoperative exploration, multisite biopsies, and prophylactic appendectomy. Ultimately, the management of such patients requires highly individualized surgical and chemotherapeutic strategies that account for the divergent biological behaviors and therapeutic sensitivities of both HGSOC and well-differentiated appendiceal mucinous adenocarcinoma to optimize oncological outcomes.

CA125 in low-grade serous ovarian cancer correlates with disease stage, reflects treatment response, and shows prognostic relevance for progression-free survival at pre-defined clinical time points. It may support recurrence detection but should not be used as a stand-alone marker.

She was treated with a methylprednisolone taper, budesonide and infliximab, resulting in resolution of symptoms. In this case, colitis was successfully managed with corticosteroids and infliximab, allowing for safe re-challenge at a reduced dose. This case highlights the importance of recognizing and managing rare toxicities associated with antibody-drug conjugates to optimize their safe use in ovarian cancer treatment.

P1, N=103, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | N=258 --> 103 | Trial completion date: Jul 2028 --> Aug 2026 | Trial primary completion date: Apr 2028 --> Aug 2026

MUC4, particularly when combined with WT1, is a promising immunohistochemical marker that may support accurate determination of tumor origin and may aid in diagnosis in challenging cases. Further validation in larger cohorts is warranted.

MSBM enables robust HRD evaluation from a whole-exome sequencing assay. Olaparib monotherapy demonstrated clinical benefit for first-line maintenance in HRD-positive ovarian cancer without bevacizumab.

An equation based on five genes (ARID1A, NOTCH3, CSMD3, ELP4, and BARD1) showed strong predictive performance for olaparib response (area under the curve = 0.91). Collectively, these findings indicate that the CNV status of EV-DNA may serve as a non-invasive companion biomarker for patient stratification and therapeutic monitoring in HGSOC.

EGFR inhibitors emerged as selective hits in NSMP cell lines and were further tested in two NSMP and two MAPK-mutant lines in combination with standard-of-care chemotherapy agents, carboplatin and paclitaxel...EGFR inhibitors (avitinib, AV-412) showed selective, low-dose synergy with standard-of-care chemotherapy in NSMP models, with minimal and inconsistent effects in MAPK-mutant lines...These findings position EGFR overexpression as a defining and targetable feature of NSMP LGSOC and support further preclinical validation of EGFR inhibitors as a treatment strategy for this understudied cancer subtype.

Independent validation in TCGA supports the potential clinical relevance of this mutational signature. These findings warrant further validation in larger prospective cohorts and functional studies to clarify their role as biomarkers of aggressive disease and therapeutic vulnerability.

This two-sample MR study provides preliminary genetic evidence that inflammatory cytokines contribute to SOC risk, with lipid metabolism partially mediating IL-8 effects. These findings highlight the interplay between inflammation and metabolism in SOC pathogenesis and suggest potential biomarkers and therapeutic targets. Due to limited sample sizes and European-only ancestry datasets, these findings require validation in larger, multi-ancestry cohorts.

These data confirm that the use of olaparib as long-term maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer is tolerable. Adverse events occurred early, were manageable, and few occurred with late onset.

P1/2, N=890, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jan 2027 --> May 2027 | Trial primary completion date: Feb 2026 --> May 2027